海泰新光跌3.03%，成交额1.18亿元，今日主力净流入-888.42万

Core Viewpoint - The company, Qindao Haitai New Light Technology Co., Ltd., is experiencing a decline in stock price while maintaining a strong position in the medical device industry, particularly in optical technology and endoscope products. The company benefits from a significant overseas revenue share and is recognized as a "specialized, refined, distinctive, and innovative" enterprise by the Ministry of Industry and Information Technology of China [2][3]. Company Overview - Qindao Haitai New Light was established on June 11, 2003, and went public on February 26, 2021. The company specializes in the research, development, production, and sales of medical endoscope devices and optical products. Its revenue composition includes 64.86% from medical endoscopes, 21.63% from optical products, 13.09% from maintenance services, and 0.42% from leasing [7]. - As of June 30, 2025, the company reported a revenue of 266 million yuan, representing a year-on-year growth of 20.50%, and a net profit of 74.44 million yuan, with a growth of 5.52% [7]. Market Position and Financials - The company has a market capitalization of 5.325 billion yuan and a trading volume of 118 million yuan, with a turnover rate of 2.18% [1]. - The average trading cost of the stock is 41.13 yuan, with the current price near a support level of 43.20 yuan [6]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 207 million yuan distributed over the past three years [8]. Investment Highlights - The company is recognized as a "little giant" enterprise, indicating its strong focus on niche markets, innovation capabilities, and high market share, which enhances its competitiveness and stability within the industry [2]. - The overseas revenue accounted for 69.12% of total revenue in the 2024 annual report, benefiting from the depreciation of the Chinese yuan [3].